By: Dr. Shane Kurth, D.C., BCN
Co-Owner, Radiant Results
Updated August 2026

This guide was prepared by the clinical team at Radiant Results. It covers what peer-reviewed research currently supports about red light therapy and the menopause transition — including skin collagen, joint comfort, body composition, and sleep — and is equally explicit about where evidence remains insufficient. It does not address intravaginal or pelvic photobiomodulation devices, which fall outside Radiant Results’ full-body clinical scope. Use this as a starting point for an informed conversation with your OB-GYN or menopause specialist.

Medical Disclaimer: This content is educational and does not constitute medical advice. Red light therapy is not a treatment for menopause. Consult a qualified healthcare provider before beginning any new wellness protocol — particularly if you are managing hormone-sensitive conditions, taking photosensitizing medications, or undergoing active cancer treatment.

Red Light Therapy for Menopause: Evidence-Based Guide for Lake Norman

Red light therapy can credibly support several menopause-era concerns. Collagen preservation and joint comfort have the strongest clinical backing. Sleep quality and body composition show early promise. Hot flashes are not currently supported by adequately powered, controlled-trial data. This modality is not a replacement for hormone therapy or medical care — but it may serve as a useful, low-risk adjunct for women navigating the menopausal transition.

Key Takeaways

• Joint and muscular discomfort is the most prevalent menopause symptom — reported by an estimated 65.43% of midlife women in a 2024 meta-analysis of 321 studies comprising 482,067 women — yet receives far less attention than hot flashes in mainstream coverage.
• Red light therapy’s strongest evidence for menopausal women lies in skin collagen stimulation and musculoskeletal pain reduction, both supported by multiple randomized controlled trials in relevant populations.
• Near-infrared light (~810–850nm) penetrates 2–5cm into tissue, reaching joint structures, muscle, and deeper connective tissue. Red light (~630–660nm) penetrates ~8–10mm and is most active in skin and superficial tissue layers.
• Hot flashes remain a category of insufficient evidence. A small pilot study exists, but no adequately powered placebo-controlled trials have confirmed red light therapy as a vasomotor intervention.
• Red light therapy works best as a complement to OB-GYN care and a comprehensive lifestyle strategy — not as a substitute for hormone therapy or physician-directed treatment.

Menopause Symptoms and Where Red Light Therapy Fits

The most commonly cited menopause symptom is the hot flash. The most prevalent one, according to a 2024 systematic review and meta-analysis of 321 studies comprising 482,067 middle-aged women, is joint and muscular discomfort — with a pooled prevalence of 65.43% (95% CI: 62.51–68.29). Hot flashes had a pooled prevalence of 52.65% in the same analysis. That gap matters for how women and their providers prioritize care.

As women move through perimenopause — typically beginning in the mid-40s, characterized by hormonal fluctuation and irregular cycles — into menopause (defined as 12 consecutive months without a menstrual period) and then postmenopause, declining estrogen affects multiple systems simultaneously. Skin collagen production slows. Joint tissue integrity changes. Inflammatory signaling shifts. Lean muscle mass becomes harder to preserve, and sleep architecture is disrupted. These are not separate problems — they share a common hormonal root.

Red light therapy does not alter hormone levels. What it targets is the downstream tissue machinery that estrogen decline destabilizes. Photobiomodulation works through a mitochondrial mechanism: photons are absorbed by cytochrome c oxidase in the mitochondrial respiratory chain, supporting increased ATP production and modulating inflammatory signaling pathways — a process Hamblin (2017) details in a peer-reviewed review of photobiomodulation mechanisms. Because this mechanism is active in skin, joint tissue, and muscle alike, a single modality can plausibly address several menopause-era concerns through one shared cellular pathway.

The Evidence by Symptom — An Honest Assessment

Different menopause symptoms have very different evidence bases for red light therapy. Presenting them as a single undifferentiated claim — “RLT helps menopause” — is how most competitor content misleads readers. The table below assigns each symptom an honest evidence tier based on the published literature.

The “Insufficient” and “Out of Scope” designations are not weaknesses in this guide — they are its most important entries. A resource that tells women where evidence does not support a claim is more trustworthy, and ultimately more useful, than one that overpromises.

For women considering a full-body red light therapy protocol, the session structure at Radiant Results delivers both red and near-infrared wavelengths simultaneously. This is relevant because different symptom categories respond to different depths of tissue penetration.

Skin and Collagen — The Strongest Clinical Case During Menopause

Dermatology literature documents that women’s skin can lose approximately 30% of its collagen during the first five years following menopause. Estrogen plays a central role in fibroblast activity and collagen synthesis. As estrogen declines, matrix metalloproteinase (MMP) enzymes — which break down collagen — become relatively more active, while fibroblast-driven collagen production slows. The result is visible skin thinning, reduced firmness, and accelerated wrinkling that is distinct from normal photoaging.

Red light at ~630–660nm penetrates ~8–10mm into the skin, reaching the dermal layer where fibroblasts reside. At this depth, photons are absorbed by cytochrome c oxidase in fibroblast mitochondria. This stimulates ATP production and activates downstream collagen and elastin synthesis. Avci et al. (2013) reviewed photobiomodulation outcomes in skin and confirmed that LED-based treatments stimulate measurable fibroblast-level collagen production. In their review of low-level light therapy for skin, reviewed split-face protocols showed measurable reductions in wrinkle depth and surface roughness in a majority of subjects.

A separate randomized controlled trial by Wunsch and Matuschka, published in Photomedicine and Laser Surgery (2014), treated 136 subjects over 30 sessions with red and near-infrared light and confirmed a statistically significant increase in intradermal collagen density measured by ultrasound compared with untreated controls — objective structural evidence, not subjective scoring. In this controlled trial of red and near-infrared light for skin rejuvenation, the treatment groups also showed significant improvements in skin complexion, skin roughness, and patient-assessed satisfaction.

One honest qualification: most skin RCTs enrolled general photoaged populations, not specifically menopausal women. The mechanism driving results is mitochondrial and fibroblast-level — it does not require estrogen to function. The clinical signal from general skin collagen studies applies directly to the menopausal context.

For more detail on skin-specific evidence, our skin rejuvenation service covers the clinical data in depth.

Safety note: Women on photosensitizing medications — including certain antibiotics, thiazide diuretics, and retinoids such as isotretinoin — should consult their prescribing provider before beginning red light therapy. Photosensitive skin conditions, including lupus and rosacea, also warrant provider review prior to treatment.

Joint Aches and Muscle Soreness — What the Research Shows

The 2024 systematic review of 321 studies comprising 482,067 middle-aged women found joint and muscular discomfort to be the single highest-prevalence symptom across the menopausal transition, at a pooled rate of 65.43% (95% CI: 62.51–68.29) — exceeding the pooled prevalence of hot flashes in the same dataset. A separate systematic review focused specifically on perimenopausal women estimated overall musculoskeletal pain prevalence at 71% (95% CI: 64%–78%). Women in their mid-40s experiencing joint changes are not anticipating menopause symptoms — they are already in them.

The evidence base for photobiomodulation and joint pain is among the strongest in the RLT literature. Stausholm et al. (2019) analyzed 22 randomized placebo-controlled trials (n=1,063) of low-level laser therapy for knee osteoarthritis. In this BMJ Open meta-analysis of low-level laser therapy for knee pain, pain was significantly reduced versus placebo at end of therapy (14.23mm on a 100mm VAS; 95% CI: 7.31 to 21.14). At recommended doses, pain reduction reached 18.71mm at end of therapy (95% CI: 9.42 to 27.99) and was sustained during follow-up periods of 2–12 weeks after therapy concluded (23.23mm VAS; 95% CI: 10.60 to 35.86).

The wavelength distinction matters here. Near-infrared light at ~810–850nm penetrates 2–5cm into tissue — deep enough to reach joint capsules, synovial tissue, periarticular muscle, and tendons. Red light at ~630–660nm penetrates ~8–10mm and is most active at the skin surface and superficial fascial layers. For musculoskeletal applications, near-infrared is the clinically relevant wavelength range. Proposed mechanisms of pain reduction include reduced pro-inflammatory cytokine production, restored mitochondrial function in damaged cells, and nitric oxide-mediated improvements in local circulation (Hamblin 2017).

An honest qualification applies: the RCT populations are general osteoarthritis and musculoskeletal pain patients, not specifically menopausal women. The pain-reduction mechanism, however, is not hormone-dependent — it operates through the same cellular pathway regardless of hormonal status.

For protocol and evidence detail on joint applications, our pain management program provides more context. Women also managing post-exercise soreness or sarcopenia risk may find red light therapy for muscle recovery useful — early-phase studies suggest photobiomodulation may support muscle recovery and reduce exercise-induced cellular damage, though menopause-specific muscle RCTs remain limited.

Safety note: Women with active rheumatoid arthritis flares, implanted electronic devices near treatment areas (including pacemakers or neurostimulators), active malignancy, or active autoimmune disease should consult their provider before beginning red light therapy. RLT is not a replacement for rheumatology care or musculoskeletal assessment for new or worsening joint symptoms.

Body Composition and Energy — Promising, With an Honest Picture

The body composition changes associated with menopause are often described simply as “weight gain,” but that framing undersells the complexity. Declining estrogen drives a shift in fat distribution — from peripheral storage toward central, visceral adiposity — alongside changes in metabolic rate, insulin sensitivity, and lean muscle preservation. These shifts occur even in women whose total body weight remains stable.

Red light therapy’s evidence base for body composition comes from randomized controlled trials in general adult populations. Jackson et al. documented statistically significant reductions in waist and hip circumference following low-level laser therapy in a randomized controlled body-contouring study (Lasers in Surgery and Medicine, 2009). Caruso-Davis et al. reported comparable findings on spot fat reduction in a separate body-contouring RCT. These are body-contouring studies — they establish that the underlying mechanism is supported in general populations, not specifically during menopause. Menopause-specific body composition RLT data, as of 2026, remains limited.

On the energy and fatigue front, the mechanistic case is plausible but not yet clinically confirmed in menopausal populations. Estrogen decline is associated with reduced mitochondrial efficiency in certain tissues. Photobiomodulation targets that same cytochrome c oxidase pathway to support ATP production (Hamblin 2017). Whether this translates to measurable fatigue reduction in menopausal women specifically is a question the current literature has not yet answered with adequately powered trials.

Radiant Results uses the Styku 3D body scanner as an objective progress-tracking tool. For women navigating menopausal body composition changes, a baseline scan at the start of an RLT series provides a data reference point for tracking changes over time — one that can be shared with an OB-GYN or primary care provider. The scanner measures; it does not treat.

The honest clinical picture: body composition changes during menopause respond most reliably to resistance training, protein-adequate nutrition, sleep optimization, and — where medically appropriate — hormone therapy. Red light therapy is an adjunct that may support those efforts. It is not a standalone body composition intervention.

What Red Light Therapy Cannot Do — Hot Flashes and Vasomotor Symptoms

Hot flashes and night sweats — collectively termed vasomotor symptoms — result from disrupted hypothalamic thermoregulation as estrogen fluctuates and declines. This is a central nervous system phenomenon involving the hypothalamic thermostat and downstream autonomic pathways. Red light therapy has no established mechanism for altering hypothalamic thermoregulation or correcting the hormonal fluctuations that trigger vasomotor events.

The most frequently cited pilot study in this space involved approximately 30 women receiving near-infrared light applied to the sternum, with no placebo control group. The study reported a reduction in hot flash frequency — a preliminary signal, not evidence of established efficacy. The appropriate characterization: a small, uncontrolled pilot study reported reduced hot flash frequency, which warrants investigation in adequately powered controlled trials, not a clinical recommendation.

Several online sources describe red light therapy as able to “regulate body temperature” or “reduce hot flash frequency and intensity” as if these are established clinical facts. They are not. Women reading across multiple sources deserve a page that states this directly.

Red light therapy does not raise estrogen, progesterone, or any other reproductive hormone. It does not replicate the systemic effects of hormone replacement therapy. Women who are appropriate candidates for HRT should have that conversation with their OB-GYN. For hot flashes specifically, the honest answer is: evidence is currently insufficient to support a clinical recommendation, and physician-guided options should be the priority.

Red Light Therapy as a Menopause Care Adjunct — Not a Replacement

Red light therapy is most accurately described as a non-hormonal, non-pharmaceutical, low-risk adjunct to evidence-based menopause care. The distinction between “adjunct” and “alternative” is not semantic — it reflects a meaningful clinical reality. The primary anchors of menopause care remain hormone therapy (systemic or local, where medically appropriate and desired), evidence-based lifestyle interventions (resistance training, protein-focused nutrition, sleep hygiene, stress reduction), and mental health support. This modality fits alongside these, not above them.

For women preparing to discuss RLT with their OB-GYN or primary care provider, the following talking points may be useful:

• “I’m interested in a non-hormonal modality that may support joint comfort and skin collagen — is there anything in my current medical history or medication list I should flag first?”
• “I’m considering using red light therapy at a medical-grade clinic — should I let you know about timing relative to any of my current treatments?”
• “I take [medication] — does that have photosensitivity implications I should be aware of before starting?”
• “I’d like to track my body composition over the course of my menopause transition — would you find that data useful to have?”
• “Are there any conditions in my history — autoimmune, skin, or otherwise — where you’d want me to hold off on this?”

Relevant contraindications for provider review before beginning red light therapy include: active malignancy, photosensitizing medications, implanted electronic devices (pacemakers, neurostimulators) near planned treatment areas, active autoimmune flares, pregnancy, and post-surgical sites. For regulatory context on photobiomodulation devices, see the FDA’s overview of light therapy devices. These are topics for a provider conversation, not absolute clinic exclusions — but they should not be skipped.

The Dahlia Full Body Medical Grade Light Therapy Bed delivers simultaneous red and near-infrared light in a 15-minute, non-invasive session within a D.C.-led clinical environment — a meaningful distinction from consumer-grade at-home devices in terms of output consistency and clinical oversight.

What to Expect at Radiant Results Lake Norman — Sessions and Timelines

Sessions at Radiant Results use the Dahlia Full Body Medical Grade Light Therapy Bed. Each session is 15 minutes. Clients are supine. Red light (~630–660nm) and near-infrared (~810–850nm) are delivered simultaneously across the full body. Sessions are non-thermal, non-invasive, and require no downtime.

The timeline below reflects what clinical evidence and clinical observation at the Lake Norman practice suggest is a reasonable expectation. These are not guarantees — individual variation in skin type, joint condition, health history, and session frequency all affect outcomes.

Women navigating perimenopause and menopause in the Lake Norman area frequently arrive with their primary focus on skin changes and energy levels. A notable share report that joint comfort improvements are the benefit they notice first — a finding that aligns with how quickly the photobiomodulation mechanism acts on inflammatory signaling relative to the slower timeline of visible collagen regeneration.

Radiant Results uses the Styku 3D body scanner for objective baseline and progress measurement. For women managing menopausal body composition changes, a documented baseline before a series of sessions begins gives both the client and their provider a meaningful data point for comparison — rather than relying on scale weight alone, which does not capture the distribution shifts that characterize menopausal body composition change.

Visit Radiant Results — Lake Norman
19824 W Catawba Ave, Suite G · Cornelius, NC 28031
📞 (704) 255-4885

Serving Cornelius, Davidson, Mooresville, and the broader Charlotte metro-north corridor.

The $79 New Patient Special includes an initial session in the Dahlia Full Body Medical Grade Light Therapy Bed plus a consultation to review health history and establish goals. Women currently working with an OB-GYN or menopause specialist are encouraged to bring relevant notes from that care relationship.

Claim the $79 New Patient Special →

Frequently Asked Questions

Does red light therapy help with menopause symptoms?

Red light therapy has credible, well-studied support for some menopause-era concerns and insufficient evidence for others. Skin collagen loss and joint pain have the strongest evidence bases, supported by multiple randomized controlled trials. Sleep quality and body composition show early promise. Hot flashes currently lack adequately powered controlled-trial data. Red (~630–660nm) light is most relevant for skin; near-infrared (~810–850nm) penetrates 2–5cm for joint and muscle concerns. RLT is best used as an adjunct to physician-guided care, not a standalone treatment.

Can red light therapy reduce hot flashes or night sweats?

The current evidence is insufficient to support red light therapy as an established intervention for hot flashes or night sweats. A small pilot study of approximately 30 women — with no control group — reported reduced hot flash frequency following near-infrared light application. This is a preliminary signal, not confirmed clinical evidence. Women seeking effective vasomotor relief should prioritize physician-guided options, including hormone therapy where medically appropriate, and discuss any adjunct modalities with their provider before starting.

What does red light therapy do for skin collagen during menopause?

Menopause-associated estrogen decline suppresses fibroblast activity and accelerates collagen breakdown, leading to visible skin thinning and loss of firmness. Red light at ~630–660nm penetrates ~8–10mm into skin — reaching the dermis — where it stimulates fibroblasts to increase collagen and elastin production through the photobiomodulation mechanism. Multiple randomized controlled trials, including ultrasound-confirmed collagen density measurements, have documented measurable increases in dermal collagen following consistent red light therapy. This is the strongest evidence category for RLT in the menopause context.

Is red light therapy effective for joint pain caused by menopause?

Joint and musculoskeletal discomfort affects an estimated 65% of midlife women per a 2024 meta-analysis of 321 studies. Near-infrared light at ~810–850nm penetrates 2–5cm into tissue — reaching joint capsules, synovial structures, and periarticular muscle — and has a strong evidence base across multiple meta-analyses of randomized controlled trials in osteoarthritis populations. RCTs specifically enrolling menopausal women with joint pain remain sparse, but the pain-reduction mechanism operates independently of hormonal status. New or worsening joint pain should always be assessed by a provider first.

Can red light therapy replace hormone replacement therapy (HRT)?

No. Red light therapy does not alter hormone levels or replicate the systemic effects of hormone replacement therapy. HRT addresses menopause at the hormonal source — estrogen, progesterone, and related pathways — while photobiomodulation addresses specific downstream tissue changes at the cellular level. Women who are appropriate candidates for HRT should discuss it with their OB-GYN. For many menopausal women, that conversation is the most evidence-supported step available. RLT is most useful as a complement to a comprehensive care plan, not a substitute for medical treatment.

Where can someone get medical-grade red light therapy near Lake Norman, NC?

Radiant Results serves the Lake Norman area, including Cornelius, Davidson, Mooresville, and the broader Charlotte metro-north corridor, at 19824 W Catawba Ave, Suite G, Cornelius, NC 28031. The Dahlia Full Body Medical Grade Light Therapy Bed — delivering simultaneous red (~630–660nm) and near-infrared (~810–850nm) light — is available on-site. You can explore the $79 New Patient Special at offer.getradiantresults.com or find location details at getradiantresults.com/locations/.

Sources

1. “Mapping global prevalence of menopausal symptoms among middle-aged women: a systematic review and meta-analysis.” BMC Women’s Health. 2024. 321 studies, 482,067 women. PMC11220992.
2. Systematic review and meta-analysis of musculoskeletal pain prevalence in perimenopausal women. Overall prevalence 71% (95% CI: 64%–78%). PMC7710408.
3. Hou Y, Jiang T, Shi Y, et al. “Photobiomodulation (PBM) for menopausal symptoms: A systematic review and meta-analysis.” Lasers in Medical Science. 2024. DOI: 10.1007/s10103-024-04020-0. PMID: 38383802.
4. Stausholm MB, Naterstad IF, Joensen J, et al. “Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials.” BMJ Open. 2019;9(10):e031142. DOI: 10.1136/bmjopen-2019-031142. PMID: 31662383.
5. Hamblin MR. “Mechanisms and applications of the anti-inflammatory effects of photobiomodulation.” AIMS Biophysics. 2017. PMC5523874.
6. Avci P, Gupta A, Sadasivam M, et al. “Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.” Seminars in Cutaneous Medicine and Surgery. 2013;32(1):41–52. PMC4126803.
7. Wunsch A, Matuschka K. “A Controlled Trial to Determine the Efficacy of Red and Near-Infrared Light Treatment in Patient Satisfaction, Reduction of Fine Lines, Wrinkles, Skin Roughness, and Intradermal Collagen Density Increase.” Photomedicine and Laser Surgery. 2014;32(2):93–100. PMID: 24286286. PMCID: PMC3926176. DOI: 10.1089/pho.2013.3616.
8. Jackson RF, Dedo DD, Roche GC, Turok DI, Maloney RJ. “Low-level laser therapy as a non-invasive approach for body contouring: a randomized, controlled study.” Lasers in Surgery and Medicine. 2009;41(10):799–809. PMID: 20014253. DOI: 10.1002/lsm.20855.
9. Caruso-Davis MK, Guillot TS, Podichetty VK, et al. “Efficacy of low-level laser therapy for body contouring and spot fat reduction.” Obesity Surgery. 2011;21(6):722–729. PMC2989526.